Stroke and HIV‐associated neurological complications: A retrospective nationwide study
There is an increased risk of stroke and other neurological complications in human immunodeficiency virus (HIV) infected patients with no large population‐based studies in the literature. We aim to evaluate the prevalence of stroke, HIV‐associated neurological complications, and identify risk factor...
Gespeichert in:
Veröffentlicht in: | Journal of medical virology 2021-08, Vol.93 (8), p.4915-4929 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | There is an increased risk of stroke and other neurological complications in human immunodeficiency virus (HIV) infected patients with no large population‐based studies in the literature. We aim to evaluate the prevalence of stroke, HIV‐associated neurological complications, and identify risk factors associated with poor outcomes of stroke among HIV admissions in the United States. In the nationwide inpatient sample with adult HIV hospitalizations, patients with primary cerebrovascular disease (CeVDs) and HIV‐associated neurological complications were identified by ICD‐9‐CM codes. We performed a retrospective study with weighted analysis to evaluate the prevalence of stroke and neurological complications and outcomes of stroke among HIV patients. We included 1,559,351 HIV admissions from 2003 to 2014, of which 22470 (1.4%) patients had CeVDs (transient ischemic attack [TIA]: 3240 [0.2%], acute ischemic stroke [AIS]: 14895 [0.93%], and hemorrhagic stroke [HS]: 4334 [0.27%]), 7781 (0.49%) had neurosyphilis, 29,925 (1.87%) meningitis, 39,190 (2.45%) cytomegalovirus encephalitis, 4699 (0.29%) toxoplasmosis, 9964 (0.62%) progressive multifocal leukoencephalopathy, and 142,910 (8.94%) epilepsy. There is increased overall prevalence trend for CeVDs (TIA: 0.17%–0.24%; AIS: 0.62%–1.29%; HS: 0.26%–0.31%; pTrend |
---|---|
ISSN: | 0146-6615 1096-9071 |
DOI: | 10.1002/jmv.27010 |